Drug Database
TA

tamsulosin + tolterodine (Roliflo OD)

✓ Approved

Ranbaxy Laboratories Limited · ADRA1A · Small Molecule

What is tamsulosin + tolterodine?

tamsulosin + tolterodine is a small molecule developed by Ranbaxy Laboratories Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesRoliflo OD
CompanyRanbaxy Laboratories Limited
Drug ClassSmall Molecule
Molecular TargetADRA1A, CHRM1, CHRM2, CHRM3, CHRM4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ranbaxy Laboratories Limited

Mechanism of Action

Molecular Targets

tamsulosin + tolterodine acts on 5 molecular targets:

ADRA1Aadrenoceptor alpha 1A (ADRA1L1, ADRA1C)
CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (EGBRS, m3AChR)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin + tolterodine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Renal and urinary disordersHypertonic bladder✓ Approved

Related Research Articles

PubMedZhonghua nan ke xue = National journal of andrology2026-11-12

[Clinical observation of Sanju Lihe decoction combined with low-intensity pulsed ultrasound in the treatment of type ⅢA prostatitis with qi stagnation and blood stasis].

Long Liuya L, Zhu Wenxiong W, Yuan Yifeng Y, Liu Tao T et al.

Objective To observe the clinical efficacy and safety of Sanju Lihe decoction combined with low-intensity pulsed ultrasound (LIPUS) in the treatment of type ⅢA prostatitis of qi stagnation and blood stasis pattern. Methods From September 2024 to December 2025, a total of 204 patients with type ⅢA prostatitis of qi stagnation and blood stasis pattern treated at the First Hospital of Hunan University of Chinese Medicine were enrolled and randomly divided equally into a control group and a treatment group. The control group received tamsulosin hydrochloride sustained-release capsules, moxifloxacin hydrochloride tablets, Sanju Lihe decoction, and health education. The treatment group was additionally treated with LIPUS on the basis of the control regimen. The treatment course lasted 4 weeks. During the treatment period, the dropped and excluded cases were recorded. Eventually, 195 cases were completed in the study, including 98 cases in the control group and 97 cases in the treatment group. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), 5-item International Index of Erectile Function (IIEF-5), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), traditional Chinese medicine (TCM) syndrome scores, uroflowmetry parameters (Qmax, Qave), grading of leukocytes and lecithin bodies in expressed prostatic secretions, clinical efficacy, and follow-up outcomes were compared between the two groups before and after treatment. Results After treatment, NIH-CPSI scores, TCM syndrome scores, and SAS/SDS scores were improved in both groups compared with baseline (P<0.05). The improvements in NIH-CPSI, IIEF-5, SAS, Qmax, Qave, and leukocyte grading in prostatic secretions were significantly better in the treatment group than those in the control group (P<0.05). No significant differences were observed between the two groups in SDS scores, TCM syndrome scores, or lecithin body grading in prostatic secretions after treatment (P>0.05). The total effective rate was 77.55% in the control group and 92.78% in the treatment group, with a significantly higher rate in the treatment group (P<0.05). At the 4-week follow-up after treatment, NIH-CPSI scores remained lower in the treatment group than in the control group (P<0.05). No serious adverse events occurred in either group during treatment. Conclusion On the basis of conventional medication and health education, Sanju Lihe decoction combined with LIPUS further relieves pain and voiding symptoms, improves sexual function, anxiety status, and uroflowmetry, and alleviates local prostatic inflammation in patients with type ⅢA prostatitis of qi stagnation and blood stasis pattern. The regimen is safe and worthy of clinical application.

PMID 43017717
Read full article →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Efficacy of human umbilical cord mesenchymal stem cells in the treatment of chronic nonbacterial prostatitis in rats].

DU Haiyan H, Zhang Kun K, Zhang Qin Q, Li Linghui L et al.

Objective To investigate the efficacy of human umbilical cord mesenchymal stem cell (hUCMSC) for the treatment of chronic nonbacterial prostatitis (CNP) model rats. Methods Thirty-two male Sprague-Dawley rats were randomized into four experimental subgroups: control, model, tamsulosin, and hUCMSC, with eight animals allocated to each group. CNP models were induced in all subgroups, except the control. After 28 days of modeling, the hUCMSC group was injected weekly with 1×106 cells/kg P5 hUCMSC cell suspension by tail vein for 4 weeks. In the control and model groups, equivalent volumes of normal saline were administered via injection. And the tamsulosin group was given daily gavage of 0.022 mg/kg tamsulosin solution for 28 days. After 4 weeks of treatment, the basic indexes including body weight, intake and water intake, and prostate index were analyzed in each group, HE staining was performed to characterize the histopathological features of the prostate. The levels of serum TNF-α, IL-1β, and IL-10 in rats were detected by ELISA. qRT-PCR was used to detect the mRNA expression of TNF-α and IL-1β in prostate tissues. And Western blot was performed to detect the protein expression of the NF-κB inflammatory pathway. Results At the end of treatment, compared with the model group, the body weight and water intake of the rats in the tamsulosin group and hUCMSC group increased significantly (P<0.05). There was a significant decline in prostate indexes and prostate wet weight (P<0.01). And interstitial inflammatory cells in prostate tissues were reduced. The levels of serum TNF-α and IL-1β and the expression of TNF-α and IL-1β mRNA in prostate tissues were significantly reduced (P<0.01). An opposite tendency was observed in IL-10 levels (P<0.01). p-IκBα/IκBα and p-NF-κB p65/NF-κB p65 ratios were significantly reduced (P<0.01). Conclusion hUCMSC improve the pathological state of rat prostate, inhibit the overexpression of pro-inflammatory factors, down-regulate the phosphorylation level of NF-κB signaling pathway, and alleviate the inflammatory response in CNP rats.

PMID 43012244
Read full article →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Effects of biofeedback electrical stimulation integrated with Chinese medicine emotional care on alleviating symptoms in the patients with chronic prostatitis/chronic pelvic pain syndrome].

Tang Xue X, Wu Hui H, Ning Gang G, Peng Ajian A et al.

Objective To evaluate the efficacy of biofeedback electrical stimulation combined with Chinese medicine emotional nursing in improving symptoms among patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods Seventy patients who met the inclusion criteria of CP/CPPS were randomly divided into the conventional group and the combined intervention group, with 35 cases in each group. The control group received oral tamsulosin sustained-release capsules along with routine care. In addition to the conventional treatment, the patients in combined intervention group received biofeedback electrical stimulation combined with Chinese Medicine emotional nursing. Biofeedback electrical stimulation was administered three times per week for a total of 8 weeks. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), International Prostate Symptom Score (IPSS), Hamilton Anxiety Rating Scale (HAMA), and Hamilton Depression Rating Scale (HAMD) were used to assess patients at baseline, 4 weeks, and 8 weeks of intervention. Results No significant differences in baseline data were observed between the two groups before the intervention (P>0.05). After 4 and 8 weeks of intervention, both groups showed significant improvements in NIH-CPSI, IPSS, HAMA and HAMD scores compared to baseline (P<0.05). Compared to the control group, the combined intervention group demonstrated significantly greater reductions in the total NIH-CPSI score, its pain subscore, IPSS score, and HAMA score at both 4 and 8 weeks (P<0.05). By the 8th week, the combined intervention group also showed a significantly greater reduction in the NIH-CPSI urination subscore and HAMD score (P<0.05). However, no statistically significant intergroup difference was found in the NIH-CPSI quality of life subscore (P>0.05). Furthermore, the combined intervention group achieved significantly higher rates of nursing satisfaction (97.05%) and overall efficacy (91.18%) compared to the control group (P<0.05). Conclusion The combined intervention of biofeedback electrical stimulation and Chinese Medicine emotional nursing can significantly alleviate urinary symptoms, pelvic pain, and anxiety-depression moods in patients with CP/CPPS. Although there was no statistically significant difference in the quality of life scores between the two groups, the combined intervention may provide potential benefits for the long-term improvement of patients' quality of life in terms of the improvement of core clinical symptoms and emotional states.

PMID 43012218
Read full article →
PubMedJAMA network open2026-11-06

Drug Therapies and Incidence of Dementia Among Adults With Overactive Bladder.

Sheyn David D, Rhodes Stephen S, Mohamed Zeinab Z, Hijaz Adonis A

Concern that anticholinergic medications for overactive bladder (OAB) are associated with increased dementia risk has encouraged a shift toward β3 adrenergic agonists, which are presumed cognitively safer. Whether this presumption is justified is uncertain. To compare the risk of incident dementia among adults initiating high-risk anticholinergic, low-risk anticholinergic, or β3 agonist therapy for OAB and to evaluate the association of treatment duration with risk. This retrospective cohort study used Epic Cosmos electronic health record data from 2012 to 2025. Adults aged 40 to 90 years newly treated for OAB within 1 year of diagnosis without preexisting dementia were included. First prescribed medication class: high-risk anticholinergics (oxybutynin, tolterodine, or solifenacin), low-risk anticholinergics (darifenacin, trospium, or fesoterodine), or β3 agonists (mirabegron or vibegron). Incident dementia by diagnosis code or dementia-specific medication. Inverse probability of treatment weighting (IPTW) and Cox proportional hazards models were used, with analyses stratified by age and sex and an exploratory landmark duration-response analysis. Among 830 393 patients (585 198 female [70.5%]; median [IQR] age, 67 [57-76] years), incident dementia occurred in 65 134 patients, with a median (IQR) follow-up ranging from 1046 (571-1809) days for β3 agonists to 1568 (857-2614) days for high-risk anticholinergics. After IPTW, high-risk anticholinergics were associated with a lower hazard of dementia than β3 agonists (hazard ratio [HR], 0.90; 95% CI, 0.87-0.93) and low-risk anticholinergics (HR, 0.93; 95% CI, 0.90-0.96); low-risk anticholinergics did not differ from β3 agonists (HR, 0.97; 95% CI, 0.93-1.01). Weighted 10-year dementia risk was highest for β3 agonists (20.0%; 95% CI, 18.8%-21.2%) and lowest for high-risk anticholinergics (18.1%; 95% CI, 17.9%-18.3%). E-values of 1.29 (high-risk anticholinergics vs β3 agonists) and 1.20 (high-risk vs low-risk anticholinergics) suggested that observed differences could be explained by a modest amount of unmeasured confounding. Longer anticholinergic duration was not associated with increased risk. In this cohort study of patients undergoing treatment for OAB, β3 agonists were not associated with a lower dementia incidence compared with anticholinergics. These findings suggest that previously reported increases in risk may reflect residual confounding rather than a pharmacological effect.

PMID 42993548
Read full article →
PubMedCureus2026-11-04

Audit of Conservative Management of Acute Ureteric Stones and Factors Influencing Treatment Outcome in the Emergency Department.

Ihedoro Ifeanyichukwu E IE, Egwuatu Ebuka E, Leepetswe Lesedi L, Abroaf Ahmed A et al.

Ureteric stones are a common cause of presentation to the emergency department. Management options include conservative therapy, urinary diversion (ureteric stent /nephrostomy), ureteroscopy, or extracorporeal shockwave lithotripsy. Conservative management is known to have a high success rate in appropriately selected patients. This audit evaluates compliance with evidence-based standards in acute ureteric stones management and identifies factors influencing successful conservative treatment. This retrospective audit reviewed 143 patients who presented with renal colic to the Emergency Department between January and December 2025 and were offered conservative management. Data collected included patient demographics, laboratory findings, CT parameters, administration of non-steroidal anti-inflammatory drugs (NSAIDS) and tamsulosin, re-presentation rates and treatment outcomes. The audit benchmarked against NICE guidelines. Data analysis was performed using descriptive statistics and appropriate statistical tests (t-test, Fisher's exact test and Mann-Whitney U test) with significance set at p < 0.05. A total of 143 patients met the inclusion criteria. The average age of patients was 48 years. This comprised 101 males (70.63%) and 42 females (29.37%). NSAIDS were administered to 103 patients (72%) at presentation, while 49 patients (34.3%) with distal ureteric stones received tamsulosin. The success rate for the conservative therapy was 93.7%. Seventeen patients (11.9%) re-presented to the emergency department with colic. Among all the variables analyzed (C-reactive protein, white blood cell (WBC), creatinine, perinephric stranding, stone position), stone size was the only variable that showed a significant association with the outcome of conservative treatment (p< 0.05). Our audit findings revealed that NSAIDS and tamsulosin were sub-optimally administered in eligible patients; however, there was a very high rate of successful conservative treatment. Stone size was the only variable that showed significant association with successful conservative treatment.

PMID 42979161
Read full article →
PubMedJournal of pediatric urology2026-11-04

After the shockwave: Alpha-1 adrenergic blockers as adjunctive therapy for pediatric urinary stones-A systematic review and meta-analysis of randomized controlled trials.

Qasem Saied Mohammed Saied SMS, Almomani Mustafa Ali MA, Kasem Necip N

Pediatric urolithiasis is a growing global health concern, and extracorporeal shockwave lithotripsy (SWL) remains the preferred non-invasive treatment for upper urinary tract stones in children. Despite favorable fragmentation rates, post-procedural fragment clearance remains a critical challenge. Although the adjunctive α1-adrenergic blockade is strongly endorsed following SWL in adults by both the AUA and EAU, its utility in the pediatric post-SWL setting remains unresolved, with no prior meta-analysis exclusively addressing this clinical context. To evaluate the efficacy and safety of adjunctive α1-adrenergic blockade - silodosin and tamsulosin - versus placebo or conservative management in children following primary SWL, with respect to stone-free rate, fragment expulsion time, postoperative pain, auxiliary intervention rates, and adverse events. We searched PubMed/MEDLINE, Scopus, Embase, and Cochrane CENTRAL from inception through March 2026 for randomized controlled trials. Eligible studies enrolled pediatric patients (≤18 years) with upper urinary tract stones undergoing primary SWL and receiving post-procedural adjunctive silodosin or tamsulosin. Dichotomous outcomes were pooled using the Mantel-Haenszel method and expressed as Risk Ratios; continuous outcomes were analyzed using the Inverse Variance method and expressed as Mean Differences. Fixed- or random-effects models were applied based on heterogeneity. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the GRADE framework. The protocol was prospectively registered with PROSPERO (CRD420261419917). Four RCTs encompassing 408 pediatric patients were included. Adjunctive α1-blockade significantly improved the single-session stone-free rate (RR = 1.16; 95% CI: 1.04-1.29; I2 = 4.9%) and reduced stone expulsion time by a mean of 2.44 days (95% CI: -3.45 to -1.43; P < 0.0001). A homogeneous 32% reduction in auxiliary intervention rates was observed across all four trials (RR = 0.68; 95% CI: 0.41-1.11; I2 = 0.0%), though statistical significance was not reached, highlighting the need for cautious interpretation due to low absolute event counts. Postoperative pain scores and analgesic consumption were consistently and significantly reduced across all included trials. Drug-related adverse events were more frequent in treatment arms (OR = 7.68; 95% CI: 1.22-48.42), but were universally mild, transient, and self-limiting, with no treatment discontinuations recorded. Adjunctive α1-adrenergic blockade following SWL in children significantly improves stone-free rates, accelerates fragment expulsion, and reduces postoperative pain with an acceptable safety profile. While these findings highlight a promising adjunctive role for medical expulsive therapy (MET), the current scarcity of pediatric literature dictates clinical caution, and larger multi-center randomized trials are required before establishing definitive, guideline-level clinical protocols, contingent on achieving adequate primary stone fragmentation.

PMID 42981863
Read full article →

+3367 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin + tolterodine